Combined targeted therapy against GLI1 and CCL2/CCR2‐TAMs can significantly inhibit EHF‐mediated CCA development, providing a promising treatment strategy for CCA patients with EHF upregulation. This evidence concerns the gene CCR2 and cholangiocarcinoma.